Imatinib and CAR T cell therapy enable sustained response in a young patient with refractory RCSD1-ABL1-positive acute lymphoblastic leukemia.

A case study published in the Annals of Hematology highlights the successful treatment of a young patient with refractory RCSD1-ABL1-positive acute lymphoblastic leukemia (ALL). The patient achieved sustained molecular remission through the use of imatinib and CAR T cell therapy. The study emphasizes the importance of RNA sequencing in identifying molecular abnormalities and recommends its use in patients requiring targeted therapy. The case demonstrates the effectiveness of monotherapy with imatinib and the potential of CAR T cell therapy as a curative treatment option for chemotherapy-resistant B cell malignancies. The study was supported by the National Natural Science Foundation of China and the Scientific Research Project of Hunan Provincial Health Commission. [Extracted from the article]